ArticlePloS one2018
Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- The prevalence of nonalcoholic fatty liver disease in people living with HIV: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia.Liver international : official journal of the International Association for the Study of the Liver · 2023Trial
- Intersections of vitamin D deficiency, HIV and chronic liver diseases.HIV medicine · 2026Review
- Prevalence and Associated Factors of Non-Alcoholic Fatty Liver Disease in People Living with HIV-1.Current HIV research · 2025Article
- Development and validation of a predictive model for metabolic syndrome in a large cohort of people living with HIV.Virology journal · 2024Article
- Fatty Liver Disease: Enter the Metabolic Era.Current HIV/AIDS reports · 2023Review
- Article
- Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key.International journal of molecular sciences · 2023Review
- Weight Gain and Metabolic Syndrome in Human Immunodeficiency Virus Patients.Infection & chemotherapy · 2022Review
- Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients.Journal of personalized medicine · 2022Article
- Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Review
- Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study.World journal of hepatology · 2021Article
- Chronic hepatitis B-associated liver disease in the context of human immunodeficiency virus co-infection and underlying metabolic syndrome.World journal of virology · 2020Review
- NASH in HIV.Current HIV/AIDS reports · 2020Review
- Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.World journal of gastroenterology · 2020Article
- Optimizing patients with non-alcoholic fatty liver disease pre-transplant.Canadian liver journal · 2020Review
- Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?Digestive diseases and sciences · 2019Review
- Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Liver as a target of human immunodeficiency virus infection.World journal of gastroenterology · 2018Review
- MASLD in PLWH on ART: Predominance of Metabolic Risk Factors and Insights From Novel Biomarkers-A Cross-Sectional Study in Wrocław, Poland.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimHIV-infected individuals are at high risk of developing nonalcoholic steatohepatitis (NASH), a leading cause of end-stage liver disease in Western countries. Nonetheless, due to the invasiveness of liver biopsy, NASH remains poorly understood in HIV mono-infection. We aimed to characterize the prevalence and predictors of NASH in unselected HIV mono-infected patients by means of non-invasive diagnostic tools.
methodsHIV-infected adults without significant alcohol intake or co-infection with hepatitis B or C underwent a routine screening program employing transient elastography (TE) with controlled attenuation parameter (CAP) and the serum biomarker cytokeratin-18 (CK-18). NASH was diagnosed non-invasively as the coexistence of fatty liver (CAP ≥248 dB/m) and CK-18 >246 U/L. Identified cases of NASH were offered a diagnostic liver biopsy. Predictors of NASH were determined by multivariate logistic regression analysis.
results202 consecutive HIV mono-infected patients were included. NASH was non-invasively diagnosed in 23 cases (11.4%). Among them, 17 underwent a liver biopsy, and histology confirmed NASH in all cases. The prevalence of NASH was higher in patients with hypertriglyceridemia (17.1%), insulin resistance defined by homeostasis model for assessment of insulin resistance (HOMA-IR) (25%), those with detectable HIV viral load (42.9%) and those with elevated ALT (53.6%). After adjustment, higher HOMA-IR (adjusted odds ratio [aOR] = 1.20, 95% CI 1.01-1.43; p = 0.03) and ALT (aOR = 2.39, 95% CI 1.50-3.79; p<0.001) were independent predictors of NASH.
conclusionsNASH, diagnosed by a non-invasive diagnostic approach employing CK-18 and TE with CAP, is common in unselected HIV mono-infected individuals, particularly in the presence of insulin resistance and elevated ALT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.